National Bank of Canada FI Has $119.09 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

National Bank of Canada FI raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 72.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 359,965 shares of the medical equipment provider’s stock after acquiring an additional 150,897 shares during the period. National Bank of Canada FI’s holdings in Intuitive Surgical were worth $119,091,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Baystate Wealth Management LLC lifted its holdings in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares in the last quarter. MCF Advisors LLC grew its stake in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 40 shares in the last quarter. Atticus Wealth Management LLC lifted its stake in Intuitive Surgical by 85.4% in the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 41 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Intuitive Surgical in the 3rd quarter valued at about $25,000. Finally, Headinvest LLC bought a new position in Intuitive Surgical during the third quarter worth about $28,000. 83.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ISRG shares. Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Piper Sandler increased their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Mizuho upped their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Wells Fargo & Company boosted their price target on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Finally, Barclays raised their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Activity at Intuitive Surgical

In other news, President David J. Rosa sold 80,710 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the transaction, the president now owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, President David J. Rosa sold 80,710 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the sale, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Myriam Curet sold 481 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $386.09, for a total value of $185,709.29. Following the completion of the sale, the executive vice president now owns 298 shares in the company, valued at approximately $115,054.82. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 226,928 shares of company stock valued at $87,833,828. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Up 1.0 %

ISRG traded up $3.71 during trading on Friday, hitting $381.36. The company’s stock had a trading volume of 1,028,858 shares, compared to its average volume of 1,492,254. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The business’s 50 day simple moving average is $385.40 and its 200-day simple moving average is $350.34. The firm has a market cap of $135.27 billion, a PE ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.00 earnings per share. Equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.